Pharma company sells cancer treatment programme in potential $200m deal
Cheshire-based Redx Pharma has today revealed a deal to sell a cancer treatment programme to Dublin company Jazz Pharmaceuticals.
Under the terms of the deal Redx will receive $3.5m up front, and up to $203m in milestone payments and royalty payments.
Redx is also eligible for incremental tiered royalties in mid-single digit percentage, based on any future net sales.
The Alderley Park firm will collaborate with Jazz to advance the programme through enabling studies.
Jazz will be responsible for all future development, regu... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...